Black Diamond Therapeutics financials
$1.87+2.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $70.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $70.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | 100.0% | — | — | — | — | — | — |
| Operating income | -$12.1M | -$11.3M | -$17.6M | -$11.0M | -$13.4M | $54.5M | -$18.3M | -$18.1M | -$22.1M | -$20.2M | -$20.9M | -$24.0M |
| Net income | -$9.9M | -$9.0M | -$15.1M | -$8.5M | -$10.6M | $56.5M | -$16.0M | -$15.6M | -$19.9M | -$18.2M | -$19.4M | -$23.0M |
| Net margin | — | — | — | — | — | 80.8% | — | — | — | — | — | — |
| Diluted EPS | $-0.17 | $-0.16 | $-0.26 | $-0.15 | $-0.19 | $0.98 | $-0.28 | $-0.28 | $-0.36 | $-0.35 | $-0.37 | $-0.45 |
| EBITDA | -$12.0M | -$11.2M | -$10.2M | -$10.9M | -$13.3M | $54.6M | -$18.2M | -$18.0M | -$22.0M | -$20.2M | -$20.8M | -$23.9M |
| Operating cash flow | -$8.0M | -$10.2M | -$6.8M | -$7.8M | -$9.2M | $53.4M | -$15.1M | -$11.3M | -$14.7M | -$21.2M | -$14.0M | -$18.4M |
| Free cash flow | -$8.0M | -$10.2M | -$6.8M | -$7.8M | -$9.2M | $53.4M | -$15.1M | -$11.3M | -$14.7M | -$21.2M | -$14.0M | -$18.4M |
| Diluted shares | 57.4M | 57.2M | 58.8M | 56.9M | 56.8M | 57.7M | 56.6M | 56.5M | 55.2M | 51.8M | 51.9M | 50.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.2M | $30.1M | $21.0M | $30.9M | $30.0M | $98.4M |
| Short-term investments | $91.3M | $88.2M | $107.7M | $104.6M | $112.8M | $54.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $125.0M | $132.9M | $143.0M | $157.7M | $166.4M | $176.2M |
| Total liabilities | $28.9M | $28.6M | $30.8M | $31.6M | $33.8M | $34.7M |
| Shareholders' equity | $96.1M | $104.3M | $112.2M | $126.2M | $132.6M | $141.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology